Business Overview

Lord's Mark Industries Limited is a BSE-listed conglomerate with a 27-year legacy operating across MedTech, Renewable Energy, and Healthcare diagnostics. The company has transformed from paper trading to becoming an integrated MedTech and sustainable infrastructure company.

Investment Highlights

  • Technology-led innovation with strong execution capabilities and long-term growth opportunities
  • High-margin Healthcare segment (IVD, MedTech, Dialysis, Genomics) synergistic with scalable Renewable Infrastructure
  • 30+ registered brands, 139 trademarks, exclusive IIT-Bombay & BARC licenses, CDSCO/CE approvals
  • ₹3,000+ crore renewable energy order pipeline backed by marquee PSU and government relationships
  • 700+ distributors, 200+ enterprise clients across 15+ states with growing SAARC and US export footprint
  • Cricket icon Rahul Dravid serves as Brand Ambassador across MedTech, Pathology and Genomics segments

Financial Projections FY25-FY29

The company provided detailed financial forecasts:

  • Revenue expected to grow 3.6x from ₹710 Cr in FY25 to ₹2,586 Cr by FY29
  • EBITDA projected to increase 8.7x from ₹75 Cr to ₹650.36 Cr
  • EBITDA margin expansion from 10.5% to 25.1% (+1460 bps)
  • Adjusted PAT expected to grow nearly 10x from ₹40 Cr to ₹422 Cr
  • Diluted EPS projected to increase from ₹1.07 to ₹9.50
  • ROCE improvement from 12% to 25% (+1300 bps)

Segment-wise Revenue Breakdown (FY25 → FY29E)

  • IVD: ₹334 Cr → ₹1,117 Cr (Largest segment by FY29, includes diagnostics, Biochemistry, Analyzer and Reagents)
  • Renalcare (Dialysis): Launches FY27 at ₹62 Cr → ₹294 Cr by FY29 (EBITDA margin 25-50% - highest in portfolio)
  • Medtech: ₹8 Cr (FY27) → ₹175 Cr (FY29) at ~34% EBITDA margin
  • Lighting & Renewables: Combined ₹301 Cr → ₹1000 Cr (Lighting: ₹225 Cr → ₹457 Cr; Solar/Renewables: ₹76 Cr → ₹543 Cr)

Healthcare (IVD+MedTech+Dialysis) is expected to contribute more than half of all incremental revenue growth over the forecast period.

MedTech Innovations and IP

Renalyx AI Dialysis (85% owned subsidiary)

  • India's first indigenous AI-based Dialysis Machine with European CE Certification
  • Patented technology with 7 years of clinical trials
  • Reduces water use by 50%+ versus conventional machines
  • Cloud-connected platform with Renal Command Center for real-time CKD tracking
  • Painless dialysis treatment capability

AI Breast Screening (C-MET collaboration)

  • Non-radiative, painless thermal mapping wearable for early detection
  • Enables rural screening without hospital infrastructure

Oncodiagnoscope (BARC collaboration)

  • Portable optical spectroscopy device for oral cancer detection
  • 20-minute non-invasive result versus multi-week biopsy cycles
  • Trialled on 12,000+ patients including at Tata Cancer Hospital

Strategic Partnerships and Licenses

  • Exclusive license for point-of-care smartphone Sickle Cell diagnostics from IIT Bombay
  • Exclusive technology transfer for Oncodiagnoscope oral cancer detection from BARC
  • AI-powered, radiation-free Breast Cancer Screening wearable from C-MET, Thrissur
  • Multiplex PCR for Myeloid Leukemia (AML-M2) from BITS Pilani
  • Partnership with MapMyGenome for making genome testing accessible in India
  • Ministry of Tribal Affairs collaboration for sickle cell screening across tribal communities
  • Distribution and technology partnerships with Philips/Cipla/Braithwaite across Solar, Lighting and Healthcare

Manufacturing Capabilities

  • In-house facility with single-roof production of rapid kits, reagents and analysers
  • Only company in India with CDSCO scope for manufacturing Rapid, Biochemistry, Serology & Analyzer machines under one roof
  • Gross margin profile: ~62% IVD, ~45% MedTech devices, ~12% Solar EPC (Company estimates)

Recent Regulatory Milestones

  • ICMR approval for Sickle Cell and Genome Testing
  • Approval to manufacture veterinary blood-testing machines
  • Only India licence to manufacture Rapid, Biochemistry, Serology & Analyzer machines under one roof
  • In-house manufacturing of blood test machines started
  • Test licence received for cancer diagnosis
  • Rudo Joint Pain Relief Oil launched (Surgical Division)
  • Surgical Division received US FDA approval

Global Expansion

  • United States: $1,000,000 maiden order for Contactless Remote Patient Monitoring (RPM) and AI Early Warning Systems (EWS)
  • ISO 13485:2016, HIPAA and IEC 60601 compliant products
  • SAARC: targeted diagnostic infrastructure deployment across Sri Lanka, Bangladesh and Nepal
  • GCC & EU: strategic dialogues initiated at Davos 2024 for MedTech distribution hubs in UAE and GCC markets

Government Projects and Order Pipeline

  • Current secured order book of ~₹2,000 Cr from UPNEDA, BREDA, EESL, APDCL, Railways, Defence and Navy
  • Broader ₹3,000+ Cr pipeline
  • Only firm holding design formula for all Indian Navy warships' lighting; lit aircraft carrier INS Vikramaditya
  • Committed to 500 MW of solar capacity over 7 years, with 100 MW+ already secured for next two years
  • Key GoI programmes: SAUBHAGYA (UPNEDA-UP, APDCL-Assam), Household Electrification (UPNEDA-UP), rural electrification of Bihar & Jharkhand via EESL

Growth Drivers

  • PM Surya Ghar: ₹75,000 Cr budget for residential solar
  • National Solar Mission targets 500 GW capacity by 2030
  • 70% of Indian deaths trace to noncommunicable diseases
  • 70-80% of medical devices in India are imported - substitution opportunity
  • National Sickle Cell Elimination Mission targets 278 districts by 2047

Market Opportunity

  • Indian MedTech: $11Bn→$50Bn (2022-30, 20.8% CAGR)
  • Diagnostics: $16.2Bn→$43.5Bn (2023-32, 11.6% CAGR)
  • Global Sickle Cell Treatment Market: $3.32Bn→$6.11Bn (2024-29, 12.9% CAGR)
  • In Vitro Diagnostics (India): $1.91Bn→$2.27Bn (2024-28, 4.4% CAGR)
  • Genome Testing (India): $0.4Bn→$1.7Bn (2024-30, 26.8% CAGR)
  • Dialysis Machine Market (India): $5Bn→$11.3Bn (2024-33, 8.83% CAGR)

ESG Initiatives

  • Targeting Net-Zero carbon emissions across operations by 2035
  • 500+ MW planned solar capacity supporting grid decarbonisation
  • Renalyx dialysis saves 50%+ water per session vs. traditional units
  • Partnered with Ministry of Tribal Affairs to screen underserved tribal populations for Sickle Cell anaemia
  • Deploying e-Smart Clinics to bring diagnostics to remote and rural locations
  • BSE-listed entity adhering to SEBI Listing Obligations and Disclosure Requirements (LODR)

Growth Roadmap 2030

  • FY 2026-27: Listing on NSE, global footprint in EU/USA/GCC, full-fledged R&D team, FPO/Preferential Allotment - ₹500 Crs
  • FY 2027-28: Whole-time manufacturing unit for Medtech; Reach 2,000 pathology labs and 1,000 Renal Care Units; execute IVD/MedTech demerger
  • FY 2028-29: Cross ₹5,000 Cr consolidated group revenue
  • FY 2030: Full operational presence across US, EU, GCC and SAARC; established as leading Indian MedTech conglomerate

Risk Factors

  • Regulatory approval timelines for new device approvals (CDSCO/US FDA/CE)
  • Government payment cycles for PSU/state receivables
  • Execution & scale-up risk for new manufacturing capacity and clinic rollout
  • Competitive intensity from global MedTech and diagnostics majors

Mitigation Strategies

  • Track record of securing approvals ahead of peers; in-house regulatory team
  • Diversified client base across states and PSUs; growing export/private mix
  • Phased capex, experienced in-house project execution team
  • Cost leadership via in-house manufacturing plus exclusive institutional IP